RESEARCH DESIGN AND METHODS -In the present study, we compared insulin sensitivity as assessed by a 4-h euglycemic ( 5 mmol/l) hyperinsulinemic ( 300 pmol/l) clamp with HOMA in 115 subjects with various degrees of glucose tolerance and insulin sensitivity.
S
everal studies consistently demonstrated that insulin resistance is a s t rong predictor of type 2 diabetes (1,2). More re c e n t l y, insulin resistance has been shown to be associated with pre v alent athero s c l e rosis (3-5). Thus, the re c o gnition of insulin resistance seems to have investigational and clinical relevance in identifying subjects at high risk of type 2 diabetes and/or cardiovascular disease.
Insulin resistance can be measured by using the glucose clamp technique (6), which is re g a rded as the re f e rence method for an accurate assessment of in vivo insulin sensitivity (7). However, this method is laborious, expensive, and there f o re unsuitable for large-scale or epidemiological studies. Several alternative methods to evaluate insulin sensitivity have been proposed during the last two decades (8-13), but, although generally less complex and less troublesome than the glucose clamp technique, none of them is as simple as is n e c e s s a ry in large-scale studies involving h u n d reds or thousands of subjects.
Homeostasis model assessment (HOMA) of insulin sensitivity was proposed about 10 years ago as a simple and inexpensive alternative to more sophisticated techniques (14) . Such a method derives an estimate of insulin sensitivity from the mathematical modeling of fasting plasma glucose and insulin concentrations. Although the HOMA has been recently used in several clinical and epidemiological studies (15-24), it has not been definitely validated. Indeed, few data are available that compare insulin sensitivity estimated by the HOMA with that m e a s u red by the glucose clamp technique ( 1 2 , 2 5 , 2 6 ) .
In the present study, we perf o rm e d euglycemic hyperinsulinemic clamp studies in combination with tracer glucose infusion to measure insulin-stimulated glucose disposal in 115 individuals with various degrees of glucose tolerance and insulin sensitivity and compared the clamp studies with the estimate of insulin sensitivity derived by the HOMA.
RESEARCH DESIGN AND M E T H O D S

Subjects
The study included 115 subjects who all u n d e rwent a glucose clamp with the format described below in our laboratory in 1995 and 1996 . A total of 53 subjects with type 2 diabetes was re c ruited among those HOMA in the assessment of insulin sensitivity regularly attending the Diabetes Clinic at the University of Ve rona who were willing to participate in the study. Of these patients, 10 were treated with diet only, and 43 were taking oral hypoglycemic agents (22 were taking sulfonylureas, 21 were taking sulfonylureas plus metformin). Patients taking insulin were excluded fro m the study, and 62 nondiabetic subjects w e re re c ruited by an advertisement. All p a rticipants underwent a physical examination and routine blood chemistry evaluation. None of them had a history of recent acute illness or clinical evidence of c a rd i o v a s c u l a r, kidney, liver, or endocrine diseases. Body composition was measure d by using bioimpedance analysis (27) . Main clinical features of the study subjects a re shown in Table 1 . All subjects gave their written informed consent to part i c ipate in the study. The protocol was app roved by the Ethical Committee of the Ve rona City Hospital.
Glucose clamp
The study consisted of a 4-h euglycemic hyperinsulinemic clamp. The clamp was c a rried out as originally described by , with the exception of the amount of insulin infused, which was lower in the present study than that used in the pioneering article by DeFronzo et al. The insulin amount was lowered to achieve serum insulin levels re s e m b l i n g those encountered after a meal. The clamp was perf o rmed in combination with 3 -[ 3 H ] -D-glucose infusion, as pre v i o u s l y re p o rted in detail (28), to assess total glucose disposal (TGD) accurately.
All studies began at 8:00 A.M. Subjects were admitted to the hospital after a 10-to 12-h overnight fast. Briefly, two Teflon cannulas were inserted: one was i n s e rted into an antecubital vein for infusion of insulin, glucose (20% dextrose), and 3 -[ 3 H ] -D-glucose, and the other was ins e rted into a contralateral heated ( 6 0 ° C ) hand vein for arterialized blood sampling. After baseline blood collections for glucose and insulin determinations, a prime constant (20 mU m i n 1 m 2 body surface area) insulin infusion was started and continued for the subsequent 240 min. The insulin prime consisted of two subsequent 5-min periods during which insulin was infused at the rate of 80 and 40 mU m i n 1 m 2 , re s p e c t i v e l y.
In nondiabetic subjects, serum insulin i n c reased from an average basal value of 76 ± 10 to a mean concentration of 292 ± 38 pmol/l in the last hour of the clamp, w h e reas the values were 108 ± 14 and 304 ± 42 pmol/l, re s p e c t i v e l y, in the diabetic subjects. Plasma glucose was clamped at 5 mmol/l by a variable glucose infusion. In diabetic subjects, plasma glucose was left to drop until euglycemia was re a c h e d (generally within 120 min) and then was maintained at that level. In the last hour of the clamp, plasma glucose variability (coe fficient of variation [CV] ) was 5% in all subjects. At 2 h after the beginning of the glucose clamp, a prime constant infusion of 3-[ 3 H ] -D-glucose was initiated at the rate of 0.45 µCi/min and was continued until the end of the study. The prime dose of labeled glucose was calculated by dividing the glucose pool (plasma glucose concentration glucose distribution volume assumed to be 25% of body weight) by the product of 1.1 by the glucose infusion rate (GIR) from 100 to 120 min of the study and then multiplying the result by the tracer infusion rate. GIR was multiplied by 1.1 to take into account the expected 10% average increase in GIR fro m 100-120 to 180-240 min of the glucose clamp. As previously re p o rted (29), with this methodological approach, a steady state of tritiated glucose specific activity is obtained from 180 to 240 min of the clamp. In fact, in the entire group we examined, mean specific activity at 180 min and at 240 min averaged 843 ± 32 and 821 ± 33 dpm/µmol, re s p e c t i v e l y, with a CV of 2.5 ± 0.3% from 180 to 240 min. During this period, blood was drawn e v e ry 10 min to measure plasma levels of glucose, serum insulin, and plasma tritiated glucose specific activity. Insulin-mediated TGD rate was calculated by dividing the 3- 
Analytical determinations
Plasma glucose was measured by using the glucose oxidase method on a Beckman Glucose Analyzer (Fullerton, CA). Seru m insulin was measured by using a doubleantibody radioimmunoassay without c ro s s -reactivity with proinsulin or splitp roinsulin products (Linco Research, St. Louis, MO). The intra-and interassay CVs of serum insulin were 2.9 and 4.7%, res p e c t i v e l y. Plasma 3-[ 3 H ] -D-glucose specific activity was determined as pre v i o u s l y described in detail elsewhere (28).
HOMA of insulin resistance
The estimate of insulin resistance by HOMA score was calculated with the formula: fasting serum insulin (µU/ml) fasting plasma glucose (mmol/l)/22.5, as described by Matthews and coworkers (12) . With such a method, high HOMA s c o res denote low insulin sensitivity (insulin resistance). The CVs of HOMA s c o res were 9.4 ± 0.7 and 7.8 ± 0.6%, re- 2.06 ± 0.14 (0.7 to 6.5) 5.98 ± 0.48 (1.1 to 13.9) TGD during clamp (µmol 34.6 ± 1.6 (17.4 to 75.9) 21.0 ± 1.1 (7.8 to 52.5) m i n -1 k g -1 f a t -f ree mass) Glucose rate of appearance 0.92 ± 0.50 ( 6.39 to 8.28) 4.1 ± 0.7 ( 5.4 to 13.4) during clamp (µmol m i n -1 k g -1 f a t -f ree mass) H y p e rtension (%) ( 160/95 2 5 . 8 5 6 . 6 mmHg or tre a t m e n t ) Obesity (%) 4 1 . 9 3 7 . 7
Data are means ± SEM (range) or %.
s p e c t i v e l y, in 20 nondiabetic subjects and 20 diabetic individuals in whom this parameter was measured three times in the fasting state at 5-min intervals. The CVs of HOMA scores were 13.8 and 11.2%, res p e c t i v e l y, in a single nondiabetic subject and in a single diabetic subject in whom this parameter was measured in the morning for 5 consecutive days.
Statistical analysis
HOMA scores and TGD rates during the glucose clamp were log-transformed to a p p roximate a normal distribution. Linear and polynomial re g ressions, Pearson' s simple correlations, and Spearm a n ' s rank correlations between HOMA score s and TGD rates were computed. HOMA scores and TGD rates in each individual were stratified into quintiles, and Cohen' s k c o e ff icient of agreement (weighted k) was computed. Weights for agreement were set at 0.00 (full disagreement), 0.25, 0.50. 0.75, and 1.00 (full agreement). All data are means ± SEM.
R E S U LT S -
The entire group exhibited a strong inverse correlation between TGD rates during the glucose clamp and HOMA scores. With raw data, linear reg ression analysis gave a Pearson' s corre l ation coefficient of 0.627 (P 0 . 0 0 0 1 ) , but the scatterplot was skewed hyperbolically (Fig. 1) . A curvilinear fitting (polynomial re g ression) of the data gave a corre l ation coefficient of 0.743 (P 0 . 0 0 0 1 ) .
With log-transformed data, the corre l a t i o n c o e fficient between HOMA scores and TGD rates was 0.820 (P 0.0001) (Fig.  2) . The correlation between log HOMA s c o res and log GIR during the clamp was v i rtually identical (r = 0.801, P 0.0001). Thus, from a statistical viewpoint, 65% of the variability of insulin sensitivity assessed by the glucose clamp technique could be accounted for by HOMA. The nonparametric Spearm a n ' s rank correlation was similar to the parametric correlation (R s = 0.855, P 0.0001). The degree of linear corre l a t i o n between log HOMA scores and log TGD rates was very similar between men and women ( 0.800 vs. 0.796), younger ( 50 years) and older ( 0.832 vs. 0.800) subjects, nonobese (BMI 2 7 k g / m 2 ) and obese ( 0.800 vs. 0 . 7 6 5 ) subjects, nondiabetic and diabetic ( 0.745 vs. 0.695) subjects, and normotensive and hypertensive ( 0.786 vs.
0.762) subjects. Thus, the results were consistent within all categories of intere s t .
The agreement in the categorization was good according to insulin sensitivity when subjects were stratified into quintiles of HOMA scores and TGD rates (weighted k = 0.63) ( Table 2 ). In part i c u l a r, when considering that the categories of higher insulin sensitivity corresponded to quintile V of TGD and to quintile I of HOMA and that the categories of greater insulin re s i stance corresponded to quintile I of TGD and to quintile V of HOMA, we found s a m e -c a t e g o ry agreement in 46% of subjects, one-quintile disagreement in 49% of subjects, and two-quintile disagreement in only 5% of subjects. Three-or four-q u i n t i l e d i s a g reement never occurre d .
C O N C L U S I O N S -
Insulin re s i s t a n c e plays a major role in the development of type 2 diabetes (1,2,30) and may also be involved in atherogenesis (3-5). Thus, the assessment of insulin sensitivity has become a frequent need for clinical investi- gators and epidemiologists and may also be useful for clinicians.
In recent years, a new clinical synd rome has been described that features the clustering of several metabolic, hemodynamic, and hemocoagulative disord e r s (31,32). Although this syndrome has been given many names, its most popular name is "insulin resistance syndrome." This name is justified by the idea that insulin resistance is the major common denominator of the abnormalities involved in the s y n d rome. Unfort u n a t e l y, the vast majority of data contributing to our knowledge about this syndrome is not based on the t rue measurement of insulin re s i s t a n c e .
During the last 20 years, the assessment of in vivo insulin sensitivity in humans has been frequently based on the use of the glucose clamp technique (6). This technique is considered the "gold stand a rd" (7), although it does not mirror the physiological condition of continuously changing glucose and insulin levels (with mutual control of the hormone on the substrate and vice versa) and of differing insulin exposure in the liver and peripheral tissues. In this re g a rd, one may conclude that no method will ever be capable of t ruly measuring insulin sensitivity, but the glucose clamp technique is the method with the fewest drawbacks, and it yields results closest to the real measure. Unfort un a t e l y, this technique is not suited for larg escale or epidemiological studies because of its complexity and high cost. Altern a t i v e methods have been proposed and used in clinical investigations, but none of them is adequate for studies involving hundreds or thousands of subjects. Indeed, all of these alternative methods include injections and/or infusions of hormones, drugs, or substrates as well as drawing several timed blood samples (8-13).
An attractive approach to estimate insulin sensitivity (or insulin re s i s t a n c e ) seems to be the HOMA, which was developed by Matthews et al. (14) with comp u t e r-aided modeling of fasting glucose and insulin concentrations. These authors found that the HOMA-based insulin re s i stance score was strongly correlated with insulin sensitivity assessed by the glucose clamp technique in both nondiabetic and diabetic subjects (r = 0.83 and 0.92, respectively) (14). However, validation of the HOMA was carried out in only a few subjects (12 nondiabetic and 11 diabetic), and the glucose clamp studies were not perf o rmed in conjunction with glucose tracer infusion, so glucose disposal could not be assessed accurately. Indeed, endogenous glucose production is not always completely suppressed by physiological hyperinsulinemia, especially in diabetic subjects (28-30), and the GIR, which maintains euglycemia during the glucose clamp, can und e restimate the exact rate of glucose disposal. In another validation study, Anderson et al. (25) compared the HOMA with the glucose clamp technique in a re l a t i v e l y g reater number of subjects (n = 55), half of whom had type 2 diabetes, and found a weaker correlation between the two meas u res (r = 0.40). However, these authors p e rf o rmed isoglycemic and not euglycemic clamp studies, which thereby led to an o v e restimation of insulin sensitivity in h y p e rglycemic individuals because of the mass effect of glucose (33). In the only other validation study we are aware of, Emoto et al. (26) compared HOMA and the glucose clamp technique in 80 type 2 diabetic subjects and found a good re l a t i o nship between the two measures of insulin sensitivity (r = 0.725, P 0.001). Unfort u n a t e l y, no isotopic evaluation of TGD was pursued in this study.
In our study, the glucose clamp methodology was combined with the glucose tracer dilution technique, and the study was perf o rmed at euglycemia in both nondiabetic and diabetic subjects. Thus, the experimental conditions were the same in all subjects, which thereby allowed us to gather a comparable measurement of TGD during insulin infusion. In this context, HOMA scores and TGD rates w e re strongly correlated, and the re s u l t s w e re consistent in the various subgro u p s that we examined (men vs. women, older vs. younger subjects, obese vs. nonobese subjects, diabetic vs. nondiabetic subjects, and hypertensive vs. normotensive subjects). Taken together, these results supp o rt the use of the HOMA as a surro g a t e index of insulin sensitivity in humans. Of course, this conclusion relies on the assumption that TGD during the clamp is the re f e rence measure of insulin sensitivity.
The HOMA score does not measure the amount of glucose metabolized per unit of body weight or lean body mass during whole-body insulinization; rather, the HOMA score explores the spontaneous homeostatic characteristics of a metabolic system by inferring what deg ree of insulin sensitivity is compatible with these homeostatic characteristics. N e v e rtheless, the HOMA ranks individuals similarly to the glucose clamp technique. In fact, in a large number of individuals with various degrees of glucose tolerance and insulin resistance, we found a strong correlation between the insulin sensitivity values generated by the two tests. In this re g a rd, the HOMA score seems to be as good a predictor of clampd e t e rmined insulin sensitivity as the short insulin tolerance test (11) or the intravenous glucose tolerance test (IVGTT) analyzed with the minimal model (34-37), the method often indicated as the best alt e rnative to the glucose clamp technique (3, 38, 39) . HOMA precision (re p ro d u c i b i li t y of the measure) seems to be comparable to the glucose clamp technique and displays a CV (10-15%) that is similar to that observed with the glucose clamp (40; R.C.B., unpublished observations). Unq u e s t i o n a b l y, the HOMA is inferior to the glucose clamp technique in terms of its accuracy in assessing insulin sensitivity, but the trade-off for this limitation lies in the ease with which large numbers of subjects can be examined with a single glucose and insulin measurement in the fasting state.
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HOMA in the assessment of insulin sensitivity One could argue that we have conducted clamp studies at relatively low insulin concentrations. Thus, the question arises whether the agreement of HOMA-estimated and clamp-measured insulin sensitivity persists when the clamp experiment is perf o rmed at higher insulin concentrations. During the years, we have collected a l a rge number of clamp studies carried out at 40 or 100 mU m i n 1 m 2 s u rf a c e area. We have recently computed the HOMA scores in subjects undergoing these studies and have found strong relationships with TGD rates during the clamp. For example, in a group 19 subjects with various degrees of insulin sensitivity and glucose tolerance undergoing a 40-mU m i n 1 m 2 s u rface area clamp (11), we found a correlation coefficient of 0 . 8 8 1 . In another series of 47 studies in which the clamp was carried out at supraphysiological insulin concentrations (100 mU m i n 1 m 2 s u rface area) (41-43), the coefficient of correlation between HOMA s c o res and TGD rates was 0 . 7 6 2 .
One could also argue that the HOMA s c o re is calculated in the fasting condition, w h e reas the TGD rate in diabetic subjects was calculated at euglycemia and not at fasting ambient hyperglycemia. Thus, one may wonder whether the two measurements are comparable. We addressed this issue by comparing HOMA scores in five subjects with type 2 diabetes whom we had examined both in the spontaneous fasting state (10.2 ± 1.1 mmol/l) and a few days later after an overnight infusion of low-dose insulin to achieve euglycemia the next morning (4.8 ± 0.4 mmol/l) (44). The mean HOMA scores were quite similar (6.98 ± 1.88 at hyperglycemia and 5.89 ± 2.17 at euglycemia, NS), and the meas u res on the two separate occasions were s t rongly correlated (r = 0.889).
F u rther support for more widespre a d use of the HOMA comes from several recent studies. For example, Haffner et al. (18) found that insulin resistance estimated by the HOMA predicts the development of type 2 diabetes in Mexicans, which is similar to the observations made in Pima Indians (2) and in Caucasians (1) with the glucose clamp technique and the IVGTT analyzed with minimal model, re s p e c t i v e l y. F u rt h e rm o re, Clement et al. (17) found that glucokinase-deficient subjects are insulin resistant either when scored by the HOMA or when evaluated by the glucose clamp technique, yet Zhang et al. (24) found a mutation of the insulin re c e p t o r substrate-1 in type 2 diabetic subjects that resulted in high HOMA scores. Finally, Kumar et al. (20) re p o rted an impro v ement in HOMA-estimated insulin resistance after troglitazone treatment of type 2 diabetic subjects in agreement with tro g l itazone effects observed in glucose clamp studies (45). Thus, the HOMA can unravel insulin resistance, whether it is associated with type 2 diabetes or pre-type 2 diabetes, or with a disruption of insulin signaling at the molecular level.
Although definite proof is lacking, it seems reasonable that HOMA cannot be used in patients with type 1 diabetes or in patients with type 2 diabetes receiving insulin treatment because assessing the spontaneous homeostatic characteristics of the metabolic system in these individuals is not possible. However, the data above rep o rting on the consistency of HOMA s c o res in type 2 diabetic subjects examined at spontaneous fasting hyperg l y c e m i a and at insulin-induced euglycemia could challenge this belief. Further studies are needed to clarify this aspect. Regard l e s s , i n s u l i n -t reated diabetic subjects re p re s e n t only a limited fraction of the diabetic population (46). Specific studies are needed re g a rding the capability of HOMA to assess insulin sensitivity in particular type 2 diabetes phenotypes such as subjects with poor insulin secretion and normal insulin sensitivity or with severe insulin re s i s t a n c e and exhausted -c e l l s .
In the three previous validation studies (12, 25, 26) , serum insulin was measured by using a standard (not human insulin-specific) radioimmunoassay. In our study, we used an insulin-specific radioimmunoassay with no significant cro s s -reactivity with p roinsulin or split-proinsulin pro d u c t s , t h e reby minimizing the interf e rence exe rted on the HOMA score by raised plasma p roinsulin levels, such as those possibly enc o u n t e red in diabetic subjects (47, 48) .
HOMA is based on measuring plasma glucose and serum/plasma insulin. Although the plasma glucose assay is known to be highly re p roducible in diff e rent laboratories, insulin assay can vary considera b l y, especially if antibodies cro s s -re a c t i n g with proinsulin or split-proinsulin pro ducts are used (49). The use of specific antiinsulin antibodies is becoming common, and fewer discrepancies among laboratories are expected to occur in the future. At present, however, comparing HOMA s c o res generated in diff e rent laboratories that used diff e rent insulin assay materials should be done with great caution. For the same reason, the use of HOMA in the clinical setting to identify insulin-resistant subjects is not recommended because a cutoff value for insulin resistance estimated with the HOMA would not be easily defined. Of course, standardization of the insulin assay may circumvent these problems. Unfort un a t e l y, standardization of the insulin assay is far from becoming a re a l i t y.
One could ask whether a physiological basis underlies the strong relationship we o b s e rved between HOMA scores and clamp TGD rates. Indeed, the HOMA is a parameter that essentially explores the ability of insulin to restrain hepatic glucose p roduction in the fasting state because basal insulin has a substantial effect on hepatic glucose production (50) but a quantitatively poor (if any) effect on peripheral glucose disposal (51). On the contrary, clamp TGD is a function mainly of peripheral responses to higher insulin concentrations (28-30). We hypothesize that HOMA s c o res and clamp TGD rates are stro n g l y c o rrelated because, in virtually all clinical conditions that are characterized by peripheral insulin resistance, hepatic insulin resistance is also evident (28, 30, 32) . This is p robably because of the fact that peripheral insulin resistance of glucose metabolism is generally associated with an impaired ins u l i n -s u p p ressed lipolysis (41, 43) . Indeed, the insulin-signaling mechanisms that cont rol glucose metabolism in the skeletal muscle and lipid metabolism in adipose tissue are somewhat common (52, 53) and are thought to be disrupted in insulin-re s i s t a n t conditions (53). One consequence of the deranged insulin signaling in adipose tissue is an exaggerated lipolysis that leads to an i n c reased flux of free fatty acids fro m adipocytes to the liver, where they contribute to the diminished ability of insulin to suppress hepatic glucose pro d u c t i o n (54). Thus, that a parameter addressing essentially hepatic insulin resistance (HOMA s c o re) is strongly related to a parameter describing to a greater extent peripheral insulin resistance (clamp TGD rate) is not s u r p r i s i n g .
In conclusion, our data suggest that the HOMA is a valuable alternative to more sophisticated techniques in the evaluation of in vivo insulin sensitivity in humans. The HOMA seems to be specifically suited to l a rge-scale studies in which only fasting blood samples are available. Nevert h e l e s s , comparing HOMA scores obtained in diff e rent studies cannot be done unless the in-sulin assay is standardized. Standard i z a t i o n of the insulin assay is also a pre requisite for i n t roducing the HOMA in clinical practice.
